BBL
ALXN

Beck Bode LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Beck Bode LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-636
Closed -$73K – 320
2020
Q3 		$73K Buy
+636
New +$68.6K 0.03% 91
2020
Q2 		– Sell
-15,715
Closed -$1.69M – 55
2020
Q1 		$1.69M Sell
15,715
-10,511
-40% -$1.03M 0.78% 33
2019
Q4 		$2.84M Buy
26,226
+710
+3% +$75.9K 1.16% 32
2019
Q3 		$2.5M Buy
25,516
+1,678
+7% +$189K 1.1% 34
2019
Q2 		$3.12M Buy
23,838
+2,318
+11% +$299K 1.39% 31
2019
Q1 		$2.91M Buy
21,520
+248
+1% +$30.8K 1.4% 28
2018
Q4 		$2.07M Buy
+21,272
New +$2.51M 1.13% 30

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Beck Bode LLC's ALXN Position: Q4 2020 in Review

Beck Bode LLC sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 636 shares — an estimated $73K sold.

Beck Bode LLC first reported a position in ALXN in Q4 2018 and held it in 7 quarters. The position peaked at $3.12M in Q2 2019. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Beck Bode LLC reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Beck Bode LLC sold 636 Alexion Pharmaceuticals shares in Q4 2020, an estimated $73K.
  • Beck Bode LLC first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 7 quarters.
  • Beck Bode LLC's Alexion Pharmaceuticals position peaked at $3.12M in Q2 2019.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Beck Bode LLC's 13F filing for Q4 2020.